In a two-compound partnership, Novartis will pay Incyte $150 million upfront plus an immediate Phase III milestone of $60 million for rights to an oral JAK1/JAK2 inhibitor being investigated in myelofibrosis.
Michael Loucks, who has led the way in investigating pharma companies for healthcare fraud, resigned from his post as acting U.S. attorney for the district of Massachusetts.
In final guidance on residual solvents, FDA accepts industry comments on testing issue, though the document may still contain hurdles for approval of some generic drugs.
Human Genome Sciences has submitted a BLA to FDA for a new interferon, Zalbin, for the treatment of hepatitis C, positioning it for a potential approval in the second half of 2010.
